Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Actavis, Inc. (ACT - Analyst Report) recently announced that it is seeking FDA approval for its generic versions of Fresenius Kabi’s Diprivan and Bayer’s (BAYRY - Analyst Report) Safyral. While Diprivan is an intravenously administered sedative and anesthetic, Safyral is an oral contraceptive.

Both Fresenius Kabi and Bayer have filed patent infringement lawsuits against Actavis for their respective drugs. The filing of the lawsuits within the stipulated time period under the Hatch-Waxman Act ensures that the FDA cannot grant final approval to Actavis’ generics for up to 30 months or the court’s decision, whichever is earlier.

According to IMS Health, total US sales of branded and generic versions of Diprivan during the 12 months ended Apr 30, 2013 were $212 million. Meanwhile, Safyral sales in the US during the same time period were about $19 million, according to IMS Health. Actavis believes it was first-to-file an abbreviated new drug application (ANDA) for a generic version of Safyral - if this is the case, Actavis would be entitled to 180 days of exclusivity on gaining FDA approval for its candidate.

Meanwhile, Actavis also launched its generic version of Novartis’ (NVS - Snapshot Report) Zometa in several countries in the EU. Actavis was first to market in Germany, Spain, Sweden, Romania and Austria. Zometa is approved for the prevention of skeletal related events in adults with advanced malignancies involving bone and the treatment of adults with tumor-induced hypercalcemia. Zometa sales in Europe, as per IMS Health, were €269.5 million in 2012.

While Actavis continues to work on driving generic product sales, the company is also working on strengthening its branded product portfolio. Last month, Actavis announced its intention to acquire Warner Chilcott plc which will result in the creation of a leading global specialty pharmaceutical company with combined annual revenues of about $11 billion. The combined company will hold the third position in the US specialty pharmaceutical market with annual revenues of about $3 billion.

Actavis currently carries a Zacks Rank #2 (Buy). We are positive on the Warner-Chilcott deal which makes strategic and financial sense.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%